Abstract: Belumosudil (KD025) is an orally active, selective inhibitor of Rho-associated coiled-coil-containing protein kinase 2 (ROCK2) that has emerged as a breakthrough therapy for chronic graft-versus-host disease (cGVHD), including its severe pulmonary manifestation, bronchiolitis obliterans syndrome (BOS). BOS is characterized by progressive, irreversible airflow obstruction and fibrosis of the terminal bronchioles following allogeneic hematopoietic stem cell transplantation. By selectively targeting the ROCK2 pathway, belumosudil exerts a unique dual mechanism of action: it restores immune homeostasis by shifting the balance of T cells from a pro-inflammatory (Th17/Tfh) to a regulatory (Treg) phenotype, and it directly inhibits pro-fibrotic signaling and collagen deposition. Clinical trials, notably the ROCKstar study, have demonstrated its efficacy and safety in heavily pretreated patients with steroid-refractory cGVHD. This review synthesizes the pharmacological activity, molecular mechanisms, structure-activity relationships, current limitations, and future perspectives of belumosudil in the context of BOS and cGVHD management.
1. Introduction
Chronic graft-versus-host disease (cGVHD) is a major, potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), occurring in 30% to 70% of recipients [4]. Pulmonary cGVHD, most commonly presenting as bronchiolitis obliterans syndrome (BOS), affects 3% to 10% of allo-HSCT recipients, with the incidence rising above 14% in patients with concomitant cGVHD [4]. BOS is characterized by progressive airflow obstruction resulting from immune-mediated damage and irreversible fibrosis of the terminal bronchioles, leading to severe restrictive lung disease and high mortality [1][4].
The standard first-line treatment for cGVHD relies on systemic corticosteroids; however, up to 70% of patients become steroid-dependent or steroid-refractory over time, necessitating second-line therapies [1]. Belumosudil (KD025, REZUROCK™) is a novel, orally active ROCK2 inhibitor developed to address this unmet need. In July 2021, it received its first approval from the US FDA for the treatment of adult and pediatric patients aged 12 years and older with cGVHD after the failure of at least two prior lines of systemic therapy [2].
2. Pharmacological Activity
Belumosudil has demonstrated robust clinical efficacy in patients with steroid-refractory cGVHD. In the pivotal phase II ROCKstar trial, patients receiving belumosudil at 200 mg once daily or 200 mg twice daily achieved an overall response rate (ORR) of 74% and 77%, respectively [2][9]. Responses were observed across all affected organ systems, including the lungs, which are notoriously difficult to treat.
For pulmonary cGVHD and BOS specifically, a combined analysis of two prospective belumosudil trials involving 59 patients with BOS demonstrated a best ORR of 32%, with 17% achieving a partial response and 15% achieving a complete response [4]. Another analysis noted that 22% of BOS patients experienced a clinically significant improvement in forced expiratory volume in 1 second (FEV1) of ≥10% [3]. Importantly, the efficacy of belumosudil in the lungs is highly dependent on the baseline severity of the disease. Response rates were 50% in patients with a baseline lung score of 1, 15% in those with a score of 2, and 0% in those with a score of 3, underscoring the critical need for early intervention before irreversible fibrotic damage occurs [6].
Pharmacokinetically, belumosudil has a mean bioavailability of 64% and reaches maximum plasma concentration (Cmax) in 1.26 to 2.53 hours at steady state. It is highly protein-bound (99.9%) and has a mean elimination half-life of 19 hours. The drug is primarily metabolized by the CYP3A4 enzyme [2].
3. Molecular Mechanism of Action
Unlike other targeted therapies for cGVHD (such as ruxolitinib or ibrutinib) that possess a single mechanism of action, belumosudil exhibits a unique dual mechanism that targets both immune dysregulation and aberrant tissue fibrosis [1][7].
Immunomodulation: The ROCK2 signaling pathway plays a pivotal role in regulating T-cell-mediated immune responses. Belumosudil inhibits ROCK2, which subsequently downregulates the phosphorylation of signal transducer and activator of transcription 3 (STAT3) and upregulates STAT5 phosphorylation. This molecular shift decreases the activation of transcription factors like RORγt and Bcl6, leading to a significant downregulation of pro-inflammatory T helper 17 (Th17) and T follicular helper (Tfh) cells. Concurrently, it enhances the proliferation of regulatory T cells (Tregs), thereby restoring immune homeostasis and immune tolerance [1][2][7].
Anti-fibrotic Activity: In the context of BOS, fibrosis is the pathological hallmark. Belumosudil directly downregulates pro-fibrotic gene expression and transforming growth factor-beta (TGF-β) signaling. It inhibits actin polymerization (from G-actin to F-actin), which reduces the formation of contractile stress fibers. Furthermore, it blocks the differentiation of fibroblasts into myofibroblasts and decreases collagen deposition. In preclinical murine models of BOS, belumosudil administration significantly decreased lung fibrosis, normalized pulmonary function, and reduced antibody and collagen deposition in the lungs to levels comparable with non-cGVHD controls [1][7].
4. Structure-Activity Relationship (SAR)
Belumosudil (chemically known as 2-[3-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide) is a small molecule designed to selectively inhibit the ROCK2 isoform [2]. It demonstrates high selectivity, with a half-maximal inhibitory concentration (IC50) of approximately 100 nM for ROCK2, compared to an IC50 of 3 µM for the ROCK1 isoform [2]. This selectivity is crucial; targeting ROCK2 specifically allows for the modulation of Th17/Treg balances and the suppression of pro-fibrotic pathways without inducing the widespread systemic toxicities that might be associated with pan-ROCK (ROCK1 and ROCK2) inhibition [1][2].
5. Current Limitations
Despite its efficacy, the clinical use of belumosudil is accompanied by several limitations and safety considerations:
Adverse Events: Belumosudil is generally well-tolerated, but common adverse events (incidence ≥20%) include infections (53%), asthenia (46%), nausea (42%), diarrhea (35%), dyspnea (33%), cough (30%), and edema (27%). Grade 3-4 adverse events include infections, decreased lymphocytes, and elevated gamma-glutamyl transferase (GGT) [2].
Drug-Drug Interactions: Because belumosudil is a substrate of CYP3A4 and P-glycoprotein, coadministration with strong CYP3A inducers (e.g., rifampin) or proton pump inhibitors (e.g., omeprazole) decreases its plasma concentration, potentially reducing efficacy. In such cases, the dosage must be increased to 200 mg twice daily [2]. Additionally, belumosudil can increase the systemic exposure of concomitant immunosuppressants like tacrolimus and sirolimus, necessitating careful monitoring and potential dose reductions to prevent over-immunosuppression [1].
Efficacy in Advanced Disease: While belumosudil shows promise in early-stage BOS, its ability to reverse damage in advanced, heavily fibrotic lung disease is highly limited. Patients with a baseline lung score of 3 showed a 0% response rate, indicating that the drug cannot reverse established, end-stage architectural distortion in the lungs [6].
Pregnancy and Lactation: Based on its mechanism of action and animal studies, belumosudil may cause fetal harm and is contraindicated during pregnancy and breastfeeding [2].
6. Future Perspectives
The therapeutic landscape for belumosudil is actively expanding. Ongoing clinical trials are investigating its use earlier in the disease course, including as a first-line or pre-emptive treatment for cGVHD and BOS. For instance, the phase II BEBOP trial (NCT05922761) is evaluating belumosudil for new-onset or early-stage BOS [1].
Combination strategies are also a major focus of future research. Studies are exploring the synergistic effects of combining belumosudil with other agents, such as ruxolitinib, rituximab, or extracorporeal photopheresis (ECP), to enhance efficacy and facilitate corticosteroid-sparing [1]. Furthermore, a novel oral suspension formulation of belumosudil is currently in clinical development. This formulation has shown similar bioavailability to the tablet and aims to improve administration for pediatric patients and adults suffering from dysphagia or upper gastrointestinal cGVHD involvement [1].
Finally, the identification of reliable biomarkers (such as ST2, sBAFF, CXCL9, and CXCL10) will be critical in the future to predict which patients are at highest risk for BOS and which are most likely to respond to ROCK2 inhibition, allowing for more personalized and timely therapeutic interventions [1].
